Several Houston-area life science research teams receive thousands in grants

research roundup

It's pay day for several Houston-area research teams thanks to two grant programs. Photo via Getty Images

Several health innovation research teams across Houston are celebrating fresh funds to go toward the development of breakthrough technologies and research projects.

In InnovationMap's latest roundup of research news, check out who received this crucial funding and how their research and work can change the standard of care across the life science industry.

Reliant doles out $100,000 to two Houston Methodist critical care physician-scientists

Reliant announced that the recipients of the Reliant Innovation Fund will be two individuals within Houston Methodist Center for Critical Care in collaboration with Texas A&M's Engineering Medicine (EnMed) program.

"Meaningful innovation is core to us at Reliant and the work these institutions, physicians and students are doing is truly amazing," says Elizabeth Killinger, president of Reliant, in a news release. "We appreciate how Houston Methodist is making a lasting difference in our community by continuing to revolutionize medicine and we are honored to support them through the EnMed program."

Dr. Hina Faisal and Dr. Asma Zainab — along with the EnMed students who will support their work — will use the funds to advance their work. An anesthesiologist and critical care physician, Faisal will lead a project on 3-D-simulated virtual reality technology to prevent delirium in critically ill patients. Zainab, who specializes in cardiovascular ICU and focuses on respiratory failure and ventilator use, will lead a project to help personalize care in lung failure, creating models specific to each patient to avoid unnecessary pressure and injury caused by ventilators, per the release.

"Innovation is at the heart of what we do," says Dr. Faisal Masud, director of the Center of Critical Care at Houston Methodist, in the release. "Thanks to Reliant's generous contribution and ongoing support, we are able to seek out new ways to provide the best quality care for our most vulnerable patients while supporting our physicians, our students and their research."

Researchers at Rice University and Texas Medical Center institutions snag grants

Six research teams have received funding from Rice University's Educational and Research Initiatives for Collaborative Health, known as ENRICH. Established in 2016, the program focuses on connecting Rice faculty with TMC institutions to encourage collaboration. Last year, more than a fifth of Rice faculty were engaged in active collaborations with TMC research partners, according to a news release.

"Partnerships with TMC are an institutional priority, and they enable our faculty to translate their research to clinical practice, directly benefiting the Houston community," says Marcia O'Malley, special advisor to the provost on ENRICH and the Thomas Michael Panos Family Professor in Mechanical Engineering, in the release. "ENRICH has been instrumental in facilitating faculty engagement with TMC partners, reducing barriers to collaboration and investing institutional resources in new partnerships."

The Provost's TMC Collaborator Fund awarded $60,000 in grants to:

Jason Hafner '98, professor of physics and astronomy at Rice, and Carly Filgueira '09, assistant professor of nanomedicine and cardiovascular surgery at Houston Methodist Research Institute, to explore the development of an optical sensor for clinical detection of cholesterol.
Lan Li, assistant professor of history at Rice; Ricardo Ernesto Nuila, associate professor of medicine, medical ethics and health policy at Baylor College of Medicine; and Fady Joudah, a poet, literary translator and physician at Baylor St. Luke's Medical Center, for a pilot study of community health care access that addresses larger questions about medical racism in Houston.
Oleg Igoshin, professor of bioengineering at Rice, and Anna Konovalova, assistant professor of microbiology and molecular genetics at the University of Texas Health Science Center at Houston's McGovern Medical School, to explore new targets for antibiotic treatment by probing the feedback loop between two important stress-response pathways in bacteria.

Additionally, Rice ENRICH and Baylor's Interdisciplinary Surgical Technology and Innovation Center (INSTINCT) awarded $60,000 in grants to:

Pulickel Ajayan, the Benjamin M. and Mary Greenwood Anderson Professor in Engineering and chair of Rice's Department of Materials Science and Nanoengineering, and Crystal Shin, assistant professor of surgery at Baylor, for development of a self-charging, wireless microsensor capable of detecting changes in flow in blood vessels that have been replaced in heart bypass surgery.
Meng Li, Noah Harding Assistant Professor in Statistics at Rice, and Gabriel Loor, associate professor of surgery at Baylor, to study inflammation following lung transplantation and search for the cause of inflammatory responses that differ between men and women.
Vaibhav Unhelkar, assistant professor of computer science at Rice, and James Suliburk, associate professor of surgery at Baylor, to explore how artificial intelligence can augment surgical training.

The Equity Innovation Center Powered by Reliant will have online resources as well as an interactive learning lab at Tellepsen Family Downtown YMCA. Photo courtesy of Urban Land Institute Houston

YMCA of Greater Houston announces equity-focused innovation center backed by Reliant

it's fun to innovate at the

Houston is the most diverse city in the nation, and the YMCA of Greater Houston is looking to do its part to promote equity innovation by opening a new center.

The Equity Innovation Center Powered by Reliant will be the first of its kind in the region, and it will operate as a space for Houstonians to gather and collaborate.

"The YMCA of Greater Houston vows to stand with our brothers and sisters who are made to feel less safe by the many recent incidents – fighting for health equity in the face of the inequities being laid bare by the COVID-19 pandemic and unjust killings," says Stephen Ives, president and CEO, YMCA of Greater Houston, in a press release. "The Y will continue expanding and strengthening its commitment to combat racism, bias, prejudice and inequalities while fighting for justice."

The center will provide resources and activities so that visitors and collaborators can "walk away with a solid learning or unlearning" of social justice issues that are prominent in both Houston and nationally.

Rolling out in three phases, the project's first step is to foster conversations, consulting, and online trainings regarding systemic racial inequities. The next two phases will include setting up an interactive learning lab at Tellepsen Family Downtown YMCA, which would come to fruition by early next year.

The project is made possible by Reliant, a partner of the YMCA of Greater Houston.

"At Reliant, we respect, recognize and celebrate that our differences shape us, and that diversity and inclusion make us stronger. We're committed to powering change and supporting progress in the places where we live and work," says Elizabeth Killinger, president at Reliant, in the release. "By powering the Equity Innovation Center, we hope to further strengthen Houston so we can harness our full potential and make lasting change for future generations."

Reliant has donated $100,000 to the project, which will be distributed in $50,000 commitments over two years. The sum is a part of Reliant and NRG's "Powering Change" initiative, which has committed $1 million to go to organizations that combat racial inequities, injustice, and related violence, according to the release.

"We are grateful Reliant is joining our efforts to implement lasting and meaningful change within our community and beyond. We know that when we work as one, we move people and communities forward," Ives says.

Stephen Ives (left) is the president and CEO of YMCA of Greater Houston, and Elizabeth Killinger is president of Reiliant. Images courtesy

Reliant and Aramco Americas have provided Houston Methodist funds to move forward pertinent research and opportunities. Courtesy of Methodist Hospital/Facebook

2 corporations write checks to go toward Houston hospital's COVID-19 efforts

money moves

Two Houston companies have doled out cash to a Houston hospital's efforts in driving innovation during the pandemic as well as moving forward in a post-COVID-19 world.

Houston Methodist received $500,000 from Houston-based Aramco Americas and $130,000 from Houston-based Reliant. Aramco's gift will go toward funding ongoing research on convalescent plasma therapy as a treatment for COVID-19 and Reliant's donation will create the Reliant Innovation Fund.

"The challenges that we have and will continue to face with the COVID-19 pandemic amplifies the need for fresh ideas to combat this disease and treat those who have been affected," says Dr. Faisal Masud, medical director of the Center for Critical Care at Houston Methodist Hospital, in a news release from Reliant. "Innovating is at the core of what we do at Houston Methodist, and this generous gift from Reliant will make a difference for patients both now and for years to come."

According to the release, $100,000 will go toward supporting students in the Texas A&M University's Engineering Medicine program, which combines engineering and medical courses to allow for students to receive a master's in engineering and a medical degree in four years. Currently, A&M is renovating a building in the Texas Medical Center that will be the future home of the program.

"The EnMed program is educating a new type of physician — one with an engineering background and a forward-thinking, innovative medical mindset. Reliant's partnership and donation will allow our students to innovate for the dynamic needs on today's clinical front lines," says Dr. Timothy Boone, director of the Houston Methodist Education Institute and Associate Texas A&M Dean, in the release.

The other $30,000 of Reliant's gift will go towards expanding the hospital's patient-centric mobile app, CareSense, which Houston Methodist has used to connect with COVID-19 patients after they have left the hospital.

Aramco's donation will be used to support Houston Methodist's plasma research on COVID-19 treatment. The hospital was the first academic medical center in the United States to get FDA approval for this type of treatment on COVID-19 patients.

"Convalescent plasma therapy has been effective in other infectious diseases and our physician-scientists are working to develop it into a first-line treatment for COVID-19," says Dr. Dirk Sostman, president at the Houston Methodist Academic Institute, in a news release from Aramco.

The treatment collects blood from recovered COVID-19 patients and infuses the plasma into currently ill COVID-19 patients in hopes that the recovered patient's plasma can provide the antibodies for the ill patient to fight off the disease.

"Houston Methodist Hospital is a world-leader in healthcare as well as research and development," says Mohammad S. Alshammari, president and CEO of Aramco Americas in the release. "Our donation is an opportunity to support the innovative work occurring there in support of the Houston community and to contribute to long-term medical solutions for this global health crisis."

Midway's GreenStreet in downtown will be the site of MassChallenge Texas' Houston program. Photo via greenstreetdowntown.com

MassChallenge Texas announces the 26 companies in its inaugural Houston cohort

Startup studs

Since announcing its entrance into the Houston innovation market in January, MassChallenge Texas has been scoring the city — and the rest of the world — for the accelerator programs inaugural cohort. Now, the organization is ready to announce its 26 startups ahead of the program's July 22 launch.

The 26 companies come from three countries and six states, and half have female founders. The startups are mostly within the health care and high tech industries — eight companies reside in each of those categories. Two companies are energy related, and one company has a social impact focus. The remaining seven companies are categorized as "general," according to the release.

"We have an incredibly diverse cohort of startups for our first MassChallenge Texas in Houston program," says Jon Nordby, managing director of MassChallenge Texas in Houston, in the news release. "The startups cross five industries, where 50 percent of the startups come from outside of Houston bringing talent from innovation hubs like New York, San Francisco, and Switzerland. Proving that Houston's global reach is not just for the Fortune 500 and that startups are looking for their place in the global economy, something that Houston is uniquely suited to offer."

As a part of MassChallenge, the selected startups aren't asked for equity in order to participate, and free coworking space, more than $250K in deals and discounts, and more prizes await the top companies at the conclusion of the six-week programming.

Throughout the accelerator, MassChallenge will provide training, guidance, and corporate connections with a large network of companies, such as Southwest Airlines, TMAC, WeWork, USAA, Upstream, Central Houston, the City of Houston, Lionstone, Midway, BAE Systems, BHP, Ingram Micro, the San Antonio Spurs, and the Houston Texans. Houston-based Reliant, an NRG company, is the latest corporate partner to join those ranks, according to the release.

Over 280 companies applied for the program, says Robert Pieroni, director of economic development for Central Houston, in the release, a clear indication for him that the Houston program was a good decision for both the city and MassChallenge.

"When we set out to find a partner to support our innovation initiatives, we were seeking a catalyst for Houston's innovation ecosystem," Pieroni says in the release. "We knew we needed an organization that matched Houston's global reach and our passion for bringing creative ideas to life through business."

Without further adieu, here are the 26 companies that begin their MassChallenge journey on July 22:

AeroGenics (Iowa,)
AeroMINE (Texas,): AeroMINE is a motionless wind turbine created for the building environment. It installs like solar panels but is more cost effective.
Animatus Biosciences, LLC (Texas): Animatus Biosciences is an R&D company focusing on the development of unique regenerative therapeutics based on our modified mRNA platform.
Ask Doss (Texas): DOSS is a Real Estate Operations System (ReOS) that will radically simplify how people search (voice activated) and transact real estate.
Bell Analytics (Texas)
Bright Angle (Texas): Bright Angle is a Pinterest style activity platform for teachers, students, parents, and admins that is the "chalkboard" of the 21st century
Camppedia Inc. (Texas): Camppedia plans to disrupt the $18B children's camps industry and in the process improve the lives of millions of working parents.
Captain (Texas): Captain is a user-friendly, multi-sided platform that connects outdoor sports adventurers and guides.
Celise (Virginia): Celise is a compostable disposables company in the foodservice industry that aims to replace and eliminate single-use plastic waste.
Combined Arms [CAX-X] (Texas): Combined Arms is a forward-thinking nonprofit that is committed to unleashing the impact of veterans on Houston.
DoBrain (Republic of Korea): DoBrain is a children's diagnosis app that detects neuropsychological markers indicative of developmental delays.
Door Space Inc. (Texas): Door Space built a cloud-based platform that automates professional credential management and verification for clinicians and their employers.
ElecTrip (Texas): ElecTrip offers city-to-city, door-to-door transportation services in private-professionally driven Teslas with Wi-Fi and laptop charging. Book online to any major Texas-based city.
FloodFrame (Texas): FloodFrame is a concealed flood protection system that utilizes the natural buoyant force of water to deploy and protect your home.
Māk Studio (Texas): Māk Studio is a fabrication studio in the heart of Houston. We design and fabricate custom walls and furniture for commercial interiors.
NeuroRescue (Ohio): NeuroRescue improves the standard of care used to treat stroke, brain injury, and cardiac arrest to increase neurological outcome by up to forty-percent.
Noleus Technologies Inc. (Texas): Noleus is a novel medical device that reduces post op ileus, saves post op hospital days and accelerates patient recovery
ORDRS (Texas)
PTC Wizard (New York): PTC Wizard helps K-12 schools streamline their scheduling and sign-up process thereby improving parent involvement and decreasing overhead.
RehabMaker Corp. (California): Rehabmaker is a manufacturer of exercise equipment that attaches to wheelchairs and allows people to move their legs.
Reveal Technologies (Texas)
Sensytec Inc. (Texas): Sensytec is revolutionizing the oil & gas, and construction industries by bringing smart cement technologies and real-time data collection.
Swoovy (Texas): Swoovy is a mobile app that connects single people and volunteer opportunities with nonprofits, as a date.
Waterdata (Ticino, Switzerland): Waterdata offers Liquidprice, an Intelligent pricing software that optimizes prices with AI by adapting to customers, competitors and market behavior quickly.
WellWorth (Texas)
Zero5 (California)

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

2024 Google search volume for terms related to investing
Number of investors
Number of businesses receiving investments in 2024
Total amount of capital invested in businesses in 2024
Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

View All Listings